A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood
; 129(9): 1143-1154, 2017 03 02.
Article
in En
| MEDLINE
| ID: mdl-27872058
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carbazoles
/
Leukemia, Myeloid, Acute
/
Antineoplastic Combined Chemotherapy Protocols
/
Fms-Like Tyrosine Kinase 3
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Blood
Year:
2017
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United States